Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Abstract: Non-alcoholic fatty liver disease (NAFLD) has become the world’s most common chronic liver disease. However, due to the lack of reliable in vitro NAFLD models, drug development studies have faced many limitations, and there is no food and drug administration-approved medicine for NAFLD treatment. A functional biomimetic in vitro human liver model requires an optimized natural microenvironment using appropriate cellular composition, to provide constructive cell-cell interactions, and niche-specific bio-molecules to supply crucial cues as cell-matrix interplay. Such a suitable liver model could employ appropriate and desired biochemical, mechanical, and physical properties similar to native tissue. Moreover, bioengineered three-dimensional tissues, specially microtissues and organoids, and more recently using infusion-based cultivation systems such as microfluidics can mimic natural tissue conditions and facilitate the exchange of nutrients and soluble factors to improve physiologica.... https://www.excli.de/excli/article/view/5892
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease ; volume:22 ; year:2023
EXCLI journal ; 22 (2023)
- Creator
-
Aasadollahei, Negar
Rezaei, Niloufar
Golroo, Reihaneh
Agarwal, Tarun
Vosough, Massoud
Piryaei, Abbas
- DOI
-
10.17179/excli2023-5892
- URN
-
urn:nbn:de:101:1-2502190900339.761369913169
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Aasadollahei, Negar
- Rezaei, Niloufar
- Golroo, Reihaneh
- Agarwal, Tarun
- Vosough, Massoud
- Piryaei, Abbas
Other Objects (12)
Non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Elevated endotoxin levels in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Correlation of non-alcoholic fatty liver disease and neurodegenerative disorders
Dietary patterns and risk of non-alcoholic fatty liver disease
Danshao Shugan Granule therapy for non-alcoholic fatty liver disease
Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
Non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Elevated endotoxin levels in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Correlation of non-alcoholic fatty liver disease and neurodegenerative disorders
Dietary patterns and risk of non-alcoholic fatty liver disease
Danshao Shugan Granule therapy for non-alcoholic fatty liver disease
Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
Non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Elevated endotoxin levels in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Correlation of non-alcoholic fatty liver disease and neurodegenerative disorders
Dietary patterns and risk of non-alcoholic fatty liver disease
Danshao Shugan Granule therapy for non-alcoholic fatty liver disease
Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel